AI integration in life sciences and clinical practice

The life sciences and healthcare sectors are increasingly integrating artificial intelligence to optimize drug development and clinical workflows.

Oracle and AstraZeneca have entered a non-binding agreement to utilize AI and real-world data to improve clinical trial recruitment. This collaboration focuses on identifying eligible candidates more efficiently across areas such as oncology, respiratory, immunology, rare diseases, and cardiovascular, renal, and metabolic diseases. The partnership aims to create a continuous learning model combining AstraZeneca’s therapeutic expertise with Oracle’s cloud computing, health data, and analytics capabilities. The companies plan to establish shared governance and reusable technical components to assess the scalability of these AI-driven approaches across different geographies and medical fields.

OpenAI is expanding its life sciences footprint through the acquisition of Orchestra Bio, a software startup specializing in AI for biotechnology. This technology is being integrated into OpenAI’s Rosalind research initiative and the Rosalind Workbench. Orchestra Bio’s technology utilizes autonomous AI agents to manage the operational complexities of drug discovery, such as tracking finances, monitoring clinical trial schedules, and coordinating workflows between disconnected departmental systems. By delegating these complex work packages to AI agents, the integration aims to bridge the gap between scientific discovery and operational execution to reduce the time required for regulatory approval.

OpenAI noted that its Rosalind model already serves major industry clients, including Moderna and Novo Nordisk. To address the delay between medical research and clinical implementation, OpenAI has deployed ‘ChatGPT for Clinicians,’ a HIPAA-compliant tool for US medical professionals. The company also utilizes HealthBench, a benchmark involving over 48,000 physician-written criteria, to evaluate AI performance in clinical scenarios.